Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that wo...
Үндсэн зохиолчид: | Foxwell, B, Andreakos, E, Brennan, F, Feldmann, M, Smith, C, Conron, M |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
2003
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.
-н: Sumariwalla, P, зэрэг
Хэвлэсэн: (2009) -
Cytokines and anti-cytokine biologicals in autoimmunity: present and future.
-н: Andreakos, E, зэрэг
Хэвлэсэн: (2002) -
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
-н: Foxwell, B, зэрэг
Хэвлэсэн: (2000) -
Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist.
-н: Neve, R, зэрэг
Хэвлэсэн: (1996) -
Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
-н: Brennan, F, зэрэг
Хэвлэсэн: (1995)